Articles published by Agenus Inc.
![](https://mms.businesswire.com/media/20240628177376/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240627922781/en/381089/5/2_Agenus-Logo.jpg)
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 27, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240617904888/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240604262147/en/381089/5/2_Agenus-Logo.jpg)
Agenus Announces Virtual Annual Shareholders Meeting
June 04, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240524248076/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240523410328/en/381089/5/2_Agenus-Logo.jpg)
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 23, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240523361904/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240516753541/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240507579927/en/381089/5/2_Agenus-Logo.jpg)
Agenus Reports First Quarter 2024 Results
May 07, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240501950583/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240424486771/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240423870121/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240412973954/en/381089/5/2_Agenus-Logo.jpg)
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
April 12, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240405412451/en/381089/5/2_Agenus-Logo.jpg)
Agenus Announces Reverse Stock Split of Common Stock
April 05, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240314955875/en/381089/5/2_Agenus-Logo.jpg)
Agenus Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240306083511/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240305957176/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240229561817/en/381089/5/2_Agenus-Logo.jpg)
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
February 29, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240226680978/en/381089/5/2_Agenus-Logo.jpg)
Agenus to Participate in Leerink Partners Global Biopharma Conference
February 26, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240131376724/en/381089/5/2_Agenus-Logo.jpg)
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20240122393173/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240105369011/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20240104722958/en/381089/5/2_Agenus-Logo.jpg)
Agenus to Participate in B. Riley Healthcare Conference
January 04, 2024
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20231220565677/en/381089/5/2_Agenus-Logo.jpg)
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
December 20, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20231211433262/en/381089/5/2_Agenus-Logo.jpg)
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
December 11, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20231107507470/en/381089/5/2_Agenus-Logo.jpg)
Agenus Reports Third Quarter 2023 Results
November 07, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20231026932669/en/381089/5/2_Agenus-Logo.jpg)
![](https://mms.businesswire.com/media/20231022881056/en/381089/5/2_Agenus-Logo.jpg)
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 22, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
![](https://mms.businesswire.com/media/20231021037175/en/381089/5/2_Agenus-Logo.jpg)
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 21, 2023
From Agenus Inc.
Via Business Wire
Tickers
AGEN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.